Targeting the Insulin-Like Growth Factor Axis in Liver Cancer
Author Information
Author(s): Wu Jennifer, Zhu Andrew X
Primary Institution: NYU Cancer Institute, NYU School of Medicine
Hypothesis
The insulin-like growth factor (IGF) axis is a crucial pathway in the development and progression of hepatocellular carcinoma (HCC) and can be targeted for therapeutic interventions.
Conclusion
Targeting the IGF axis shows promise as a potential treatment strategy for hepatocellular carcinoma.
Supporting Evidence
- Hepatocellular carcinoma (HCC) is the 5th most common cancer worldwide, with a rising incidence in the US.
- Current treatments for advanced HCC are limited, highlighting the need for new therapeutic strategies.
- Preclinical studies indicate that the IGF axis plays a significant role in HCC development and progression.
Takeaway
Scientists are looking at a system in our body called the IGF axis to help treat liver cancer. This system is important for how cancer grows, and new medicines are being tested to see if they can help.
Methodology
This review summarizes preclinical and clinical data regarding the IGF axis in HCC and discusses various therapeutic strategies targeting this pathway.
Limitations
The review primarily focuses on preclinical data and early clinical trials, which may not fully represent the efficacy of IGF-targeting therapies in broader patient populations.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website